P21 is marketed in research-compound circles as a cognitive-enhancement peptide, often described with reference to neurotrophic (nerve-growth-supporting) mechanisms. We set out to find the human research underlying those claims and found a body of evidence substantially thinner than the marketing language implies.
What We Could Actually Find
The published literature on P21 is limited almost entirely to cell culture and animal studies examining neurotrophic signaling pathways — legitimate basic research, but with no human clinical trials we could locate testing cognitive effects, safety, or dosing in people.
“We went looking for the human studies behind the marketing claims and essentially came back empty.”
— from this newsletter’s own literature search for this pieceHow the Marketing Outpaces the Research
Product descriptions for P21 use confident, specific cognitive-benefit language that has no corresponding human study to point to — a pattern this newsletter has flagged before with other compounds, but notably pronounced here given how little published research exists at all.
What a Buyer Is Actually Being Sold
Absent human data, a buyer purchasing P21 is, in an evidentiary sense, participating in an uncontrolled, undocumented experiment on themselves — a description that applies to many compounds in this category to some degree, but applies with unusual sharpness here given the near-total absence of human research to even weigh.